注射用丹参多酚酸治疗急性大动脉粥样硬化型脑梗死的疗效

目的 评价注射用丹参多酚酸对急性大动脉粥样硬化型脑梗死患者的临床疗效及安全性。方法 收集2016年9月-2017年8月山西医科大学第一医院收治的急性脑梗死患者100例，随机分为对照组及观察组，各50例。对照组予常规治疗，观察组在对照组基础上加用注射用丹参多酚酸，每次0.13 g加入250 mL 0.9%氯化钠中静滴，1次/d，治疗周期均为14 d。比较两组患者治疗前和治疗后神经功能缺损（NIHSS）评分、Barthel指数（BI）评分、血纤维蛋白原（FIB）、肝肾功能、心肌酶的变化以及不良反应。结果 治疗后，两组的NIHSS评分和BI评分均有显著改善（P<0.05），且观察组NIHSS评分低于对照组（P<0.05），BI评分高于对照组（P<0.05）；观察组血FIB与治疗前比较具有统计学差异（P<0.05）。两组患者用药前后肝肾功能、心肌酶未见明显变化，用药过程中无不良事件发生。结论 注射用丹参多酚酸可以改善急性大动脉粥样硬化型脑梗死患者的NIHSS评分和BI评分，并能在一定程度上降低血FIB水平；对患者的肝功能、肾功能、心肌酶等无明显影响，副作用小。

Therapeutic effect of Salvianolic Acids for Injection in treatment of acute large artery atherosclerotic cerebral infarction

Objective To evaluate the clinical effect and safety of Salvianolic Acids for Injection (SAFI) in treatment of acute aortic atherosclerotic cerebral infarction. Methods A total of 100 patients of acute aortic atherosclerotic cerebral infarction in The First Hosipital of Shanxi Medical University from September 2016 to August 2017 were selected and were randomly divided into the observation group and the control group. The patients in the control group received routine medicine therapy, and the patients in the treatment group received SAFI 0.13 g added for 0.9% sodium chloride 250 mL intravenous drip qd in addition to the treatment of control group. Patients treated once per day and 14 d for one course of treatment, and the prognosis of the two groups were observed by NIHSS scores and BI scores, fibrinogen (FIB), liver and kidney function, myocardial enzymes and incidence of adverse reactions. Results After treatment, the NIHSS score and BI score in both groups were significantly improved (P<0.05), and the NIHSS score in the observation group was lower than that in the control group (P<0.05), and the BI score was higher than that in the control group (P<0.05). The FIB of blood in the experimental group was significantly different from that before treatment (P<0.05). The liver and kidney functions and myocardial enzymes of the two groups did not change significantly before and after treatment, and no adverse events occurred during the medication process. Conclusion SAFI can improve NIHSS scores and BI scores of patients with acute atherosclerotic cerebral infarction, and reduce blood FIB level to a certain extent. Additionally, it has no obvious effect on liver function, kidney function and myocardial enzyme, and has little side effect.